Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Seddon, Beatrice; Strauss, Sandra J; Whelan, Jeremy; Leahy, Michael; Woll, Penella J; Cowie, Fiona; Rothermundt, Christian; Wood, Zoe; Benson, Charlotte; Ali, Nasim; +9 more... Marples, Maria; Veal, Gareth J; Jamieson, David; Küver, Katja; Tirabosco, Roberto; Forsyth, Sharon; Nash, Stephen; Dehbi, Hakim-Moulay; Beare, Sandy; (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The Lancet Oncology, 18 (10). pp. 1397-1410. ISSN 1470-2045 DOI: https://doi.org/10.1016/s1470-2045(17)30622-8

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/s1470-2045(17)30622-8

Abstract

Share

Download

Filename: 010.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar